Alejandro Gutierrez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2514311/publications.pdf

Version: 2024-02-01

72 papers

6,331 citations

109264 35 h-index 60 g-index

74 all docs

74 docs citations

times ranked

74

11120 citing authors

#	Article	IF	CITATIONS
1	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014, 346, 1373-1377.	6.0	665
2	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 2011, 471, 104-109.	13.7	558
3	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 647-650.	0.6	414
4	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	13.7	355
5	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	9.4	333
6	An "off-the-shelf―fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia, 2018, 32, 1970-1983.	3.3	282
7	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 209-221.	7.7	262
8	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
9	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discovery, 2014, 4, 1074-1087.	7.7	201
10	Liquid Chromatography/Electron Capture Atmospheric Pressure Chemical Ionization/Mass Spectrometry:  Analysis of Pentafluorobenzyl Derivatives of Biomolecules and Drugs in the Attomole Range. Analytical Chemistry, 2000, 72, 3007-3013.	3.2	197
11	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2014, 124, 644-655.	3.9	180
12	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood, 2011, 118, 4169-4173.	0.6	162
13	METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell, 2021, 81, 3323-3338.e14.	4.5	153
14	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	7.7	141
15	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood, 2012, 120, 3764-3773.	0.6	132
16	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood, 2014, 123, 1040-1050.	0.6	129
17	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	4.6	124
18	TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2013, 3, 564-577.	7.7	122

#	Article	IF	CITATIONS
19	Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. British Journal of Haematology, 2007, 138, 169-175.	1.2	115
20	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood, 2010, 115, 2845-2851.	0.6	112
21	The TAL1 complex targets the <i>FBXW7</i> tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2013, 210, 1545-1557.	4.2	107
22	NOTCH and PI3K-AKT Pathways Intertwined. Cancer Cell, 2007, 12, 411-413.	7.7	106
23	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	4.2	104
24	Absence of Biallelic $\langle i \rangle$ TCR $\langle i \rangle$ Î 3 Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	0.8	93
25	Alu elements mediate <i>MYB</i> gene tandem duplication in human T-ALL. Journal of Experimental Medicine, 2007, 204, 3059-3066.	4.2	85
26	Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica, 2014, 99, 94-102.	1.7	84
27	Liquid chromatography–mass spectrometry (LC–MS) of steroid hormone metabolites and its applications. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 546-555.	1.2	78
28	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell, 2019, 35, 664-676.e7.	7.7	70
29	Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood, 2010, 115, 1735-1745.	0.6	61
30	Aberrant AKT activation drives well-differentiated liposarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16386-16391.	3.3	50
31	Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 1819-1827.	3.3	49
32	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2017, 7, 1336-1353.	7.7	48
33	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 2126-2137.	3.3	48
34	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	0.5	47
35	Shared acquired genomic changes in zebrafish and human T-ALL. Oncogene, 2011, 30, 4289-4296.	2.6	42
36	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes and Development, 2017, 31, 1456-1468.	2.7	41

#	Article	IF	CITATIONS
37	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. Cancer Discovery, 2020, 10, 1690-1705.	7.7	38
38	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 3094-3114.	4.2	37
39	A strategy to improve treatmentâ€related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. Pediatric Blood and Cancer, 2015, 62, 1395-1402.	0.8	34
40	Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. Molecular and Cellular Biology, 2009, 29, 5911-5922.	1.1	33
41	NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. PLoS ONE, 2012, 7, e39725.	1.1	31
42	Acute myeloid/Tâ€lymphoblastic leukaemia (<scp>AMTL</scp>): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. British Journal of Haematology, 2018, 180, 919-924.	1.2	29
43	Identification of prognostic factors in childhood Tâ€cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05â€001 and 11â€001. Pediatric Blood and Cancer, 2021, 68, e28719.	0.8	26
44	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 1929-1945.	4.2	22
45	Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. Advances in Experimental Medicine and Biology, 2016, 916, 335-369.	0.8	19
46	Loss of function <i>tp53</i> mutations do not accelerate the onset of <i>myc</i> êinduced Tâ€cell acute lymphoblastic leukaemia in the zebrafish. British Journal of Haematology, 2014, 166, 84-90.	1.2	16
47	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS ONE, 2019, 14, e0221288.	1.1	16
48	Ganglioneuromas are driven by activated AKT and can be the rapeutically targeted with mTOR inhibitors. Journal of Experimental Medicine, 2020, 217, .	4.2	12
49	PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. Leukemia, 2021, 35, 679-690.	3.3	11
50	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2022, 36, 1499-1507.	3.3	6
51	An X-linked tumor suppressor in T-ALL. Blood, 2015, 125, 3-4.	0.6	4
52	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. American Journal of Hematology, 2010, 85, 135-137.	2.0	3
53	Supramolecular assembly of GSK3 \hat{i} ± as a cellular response to amino acid starvation. Molecular Cell, 2022, 82, 2858-2870.e8.	4.5	3
54	Leukemia Propagating Cells Akt Up. Cancer Cell, 2014, 25, 263-265.	7.7	2

#	Article	IF	CITATIONS
55	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. Blood, 2012, 120, 3558-3558.	0.6	2
56	An Off-the-Shelfâ,,¢ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies. Blood, 2017, 130, 844-844.	0.6	2
57	Thymocyte transformation enhanced. Nature Medicine, 2014, 20, 1096-1097.	15.2	1
58	Pathobiology of Acute Lymphoblastic Leukemia. , 2018, , 1005-1019.e11.		1
59	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 604-604.	0.6	1
60	Molecular Targeted Therapies in T-Cell Acute Lymphoblastic Leukemia. , 2010, , 19-30.		1
61	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Cell Biology, 2011, 194, i4-i4.	2.3	1
62	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	0.6	1
63	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. , 2019, 231, .		1
64	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias Blood, 2006, 108, 1405-1405.	0.6	0
65	Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL Blood, 2006, 108, 1408-1408.	0.6	0
66	Pten Inactivating Mutations Promote Loss of MYC "Oncogene Addiction―in a Conditional Zebrafish Model of T-ALL Blood, 2009, 114, 3977-3977.	0.6	0
67	Cell and molecular biology of human leukaemias. , 2010, , 4214-4221.		0
68	Abstract PR02: Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL. , $2014, , .$		0
69	Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. , 2014, , .		0
70	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. Blood, 2018, 132, 889-889.	0.6	0
71	Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias. Blood, 2019, 134, 169-169.	0.6	0
72	SOD2 Promotes Acute Leukemia Adaptation to Amino Acid Starvation Through the N-Degron Pathway. Klinische Padiatrie, 2022, , .	0.2	0